KEI Briefing Note 2022:1, Selected U.S. Government COVID Contracts with Authorization and Consent to Non-Voluntary Use Of Third Party Patents
BARDA
Texas A&M Vaccine Manufacturing Contract Shows that cGMP Manufacturing of COVID-19 Vaccines Can Start in Five Months
A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading
Diversity of contract terms illustrates need for transparency of Covid-19 contracts
One of the characteristics we have seen in our analysis of COVID-19 contracts is heterogeneity. The Bayh-Dole was enacted in 1980 to provide for uniform provisions on funding agreements regarding the ownership of inventions and the public’s rights. But for… Continue Reading
Regeneron failed to disclose BARDA funding in their REGN-COV2 patent
Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge U.S. government funding in patents is required under an existing contract between Regeneron and the Biomedical Advanced Research and Development… Continue Reading
KEI Research Note 2020:4 Regeneron failed to disclose BARDA funding in their REGN-COV2 patent
KEI Research Note 2020:4 Regeneron failed to disclose BARDA funding in their REGN-COV2 patent Luis Gil Abinader October 20, 2020 Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge… Continue Reading
KEI Sues HHS and the Army over Access to COVID-19 Contracts
On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading
COVID-19 Contracts
United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading
BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications
(More on Moderna here: https://www.keionline.org/moderna) KEI received a letter Dr. Gary Disbrow, the Acting Director of BARDA, just before noon today. BARDA2KEI.Moderna.Patent.Disclosures.20200903 The BARDA investigation follows the announcement on Saturday that DARPA was also investigating DARPA’s failures to disclose DARPA… Continue Reading
KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications
On September 2, 2020, Knowledge Ecology International (KEI) sent a letter to the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential failure by Moderna, Inc. to disclose federal funding in patents supported by BARDA. KEI requested information concerning… Continue Reading
Moderna
KEI Reports and Posts 2020. October 8. KEI on Moderna’s Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic. https://www.keionline.org/34112 2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding… Continue Reading